Ultragenyx Pharmaceutical Inc. Share Price

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 15/06/2024 am IST 5-day change 1st Jan Change
39.05 USD -9.44% Intraday chart for Ultragenyx Pharmaceutical Inc. -6.51% -18.34%
Sales 2024 * 512M 42.77B Sales 2025 * 618M 51.65B Capitalization 3.9B 326B
Net income 2024 * -560M -46.78B Net income 2025 * -492M -41.1B EV / Sales 2024 * 7.16 x
Net cash position 2024 * 236M 19.74B Net cash position 2025 * 301M 25.12B EV / Sales 2025 * 5.82 x
P/E ratio 2024 *
-6.56 x
P/E ratio 2025 *
-7.89 x
Employees 1,276
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day-9.44%
1 week-6.51%
Current month-2.72%
1 month-4.66%
3 months-19.57%
6 months-12.74%
Current year-18.34%
More quotes
1 week
38.16
Extreme 38.16
45.59
1 month
37.82
Extreme 37.82
45.59
Current year
37.82
Extreme 37.82
54.56
1 year
31.52
Extreme 31.52
54.56
3 years
31.52
Extreme 31.52
104.38
5 years
31.52
Extreme 31.52
179.65
10 years
31.52
Extreme 31.52
179.65
More quotes
Managers TitleAgeSince
Founder 63 22/10/22
Director of Finance/CFO 47 16/23/16
Chief Tech/Sci/R&D Officer - 01/17/01
Members of the board TitleAgeSince
Director/Board Member 61 06/17/06
Founder 63 22/10/22
Chairman 66 08/15/08
More insiders
Date Price Change Volume
15/24/15 39.05 -9.44% 4 107 664
13/24/13 43.12 -3.41% 1,246,733
12/24/12 44.64 +7.83% 1,517,932
11/24/11 41.4 -1.36% 481,737
10/24/10 41.97 +1.38% 486,183

Delayed Quote Nasdaq, June 15, 2024 at 01:30 am IST

More quotes
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
43.12 USD
Average target price
90.05 USD
Spread / Average Target
+108.83%
Consensus